Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Hypersensitivity: early-phase trial registry

1 of 9 indexed Hypersensitivity trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Hypersensitivity: 9 US clinical trials tracked, 1 recruiting.

Hypersensitivity is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 4 of these trials.

Enrollment posture brief

Registry condition hypersensitivity

OPEN 1 | RECR 11% | LATE 1 | EARLY 2 | RANK #1916 | SPON 4

Volume-matched condition peers

Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%Hypersensitivity (this)11%
Open-enrollment share among volume-matched conditions near Hypersensitivity

Hypersensitivity lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hypersensitivity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hypersensitivity is recruiting below its size-band peers.

    1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hypersensitivity research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 4 of 9 trials (44.4%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Hypersensitivity trials plan to enrol fewer than 100 people.

    Median target enrolment is 95 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Hypersensitivity splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 1

Top Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 4 trials
David Van Sickle 1 trials
SynergEyes 1 trials
Colgate Palmolive 1 trials
National Institute of Environmental Health Sciences (NIEHS) 1 trials
GlaxoSmithKline 1 trials

Named interventions

Most-linked intervention names on Hypersensitivity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Propeller Health intervention Device
1 trials
Nupro - Fluoride Free Device
1 trials
Arginine/Calcium Carbonate Device
1 trials
Soluble recombinantly produced IL-4R Drug
1 trials
Test Toothpaste Drug
1 trials
Negative Control Toothpaste Drug
1 trials
Ragweed immunotherapy (IT) Biological
1 trials
Placebo rush immunotherapy (RIT) Biological
1 trials

US sites by state

Facility locations filed on Hypersensitivity trials. A trial with sites in several states counts in each.

Maryland 3 trials
Wyoming 1 trials
Wisconsin 1 trials
Tennessee 1 trials
Rhode Island 1 trials
Pennsylvania 1 trials
Ohio 1 trials
Nevada 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hypersensitivity page

9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypersensitivity condition card totals 9 registered trials; most-linked intervention Propeller Health intervention; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.